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Objectives: We determined the effects of vitamin B6 adjunctive therapy on linezolid-associated
cytopenias, and retrospectively studied 75 septic patients who received at least 7 days of linezolid
treatment.
Methods: Patients were divided into a linezolid treatment group (LTG; n ¼ 41) that received linezolid
only and a combination treatment group (CTG; n ¼ 34) that received both linezolid and vitamin B6.
Each group was further subdivided into those with sepsis and those with severe sepsis. Each patient had
red blood cell (RBC), hemoglobin (Hb), hematocrit (Hct), and platelet (PLT) measurements at baseline
(day 0) and every other day for 2 weeks during treatment; these parameters were compared between
the groups and assessed for time-dependent trends.
Results: For patients in the LTG, RBC, Hb, and Hct values showed statistically signiﬁcant reductions over
time, and these values were lower compared with the values in the CTG. The CTG also showed
downward trends, except on the ﬁrst day of treatment. The PLT count also decreased in both groups.
Patients with severe sepsis had lower PLT counts in both treatment groups compared with the septic
patients.
Conclusions: Septic patients who received a combination treatment of linezolid and vitamin B6 might
show positive effects for linezolid-associated reductions in some hematologic parameters (RBC, Hb, and
Hct). This combined treatment might also slow PLT reduction, which was more evident in patients with
severe sepsis. ClinicalTrials.gov identiﬁer: NCT01295801.
& 2013 . The Authors. Published by Elsevier Inc. Open access under CC BY license.Introduction
Sepsis occurs frequently, has a high mortality rate, incurs high
treatment costs, and is 1 of the leading causes of death in an
intensive care unit (ICU). Thus, it is of great importance to expand
the range of treatment options for patients with severe sepsis to
achieve higher survival rates. The primary pathogens involved in
sepsis infections are gram-positive bacteria. However, for ICUier Inc.
Department of Respiratory
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.
Open access under CC BY licepatients, the number of infections due to drug-resistant, gram-
positive bacteria is increasing, especially those due to Staphylo-
coccus aureus, coagulase-negative staphylococci and enterococci,
and methicillin-resistant Staphylococcus aureus (MRSA)1; these
infections pose a pressing problem in the treatment of patients
with sepsis.
Vancomycin and linezolid are among the ﬁrst treat-
ment choices for MRSA infections.2 However, a number of
vancomycin-resistant strains of MRSA have been reported.1 The
high efﬁcacy of linezolids, a new line of antibacterial drugs that
was introduced within the past decade, has made valuable
contributions to the treatment of vancomycin-resistant strains
of MRSA.3 However, as linezolids have become more widely used,
their adverse effects on the circulatory system,4 including anemia
and thrombocytopenia,5 have become more prominent, thus
limiting their clinical applications. However, Spellberg et al6
reported that combination therapy with vitamin B6 could reversense.
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events.
Thus, the purpose of this retrospective study was to further
explore how the application of vitamin B6 as an adjuvant
treatment affects linezolid-associated cytopenias in septic
patients.Table I
Clinical characteristics of septic patients receiving various treatments.
Variable Linezolid þ Vitamin B6
(n ¼ 34)
Linezolid
(n ¼ 41)
P
Age, y, mean (SD) 56.8 (21.9) 61.8 (18.5) 0.082
Gender, n (%) 0.395
Male 20 (68.8) 28 (68.3)
Female 14 (41.2) 13 (31.7)
Duration of linezolid, d, mean
(SD)
15.9 (8.2) 14.2 (6.2) 0.379
APACHE II, mean (SD) 15.7 (5.8) 19.2 (7.4) 0.194
Blood product transfusion, n (%) 22 (64.7) 24 (58.5) 0.585
Hemoﬁltration, n (%) 6 (17.6) 5 (12.2) 0.506
Underlying disease
Hypertension , n (%) 7 (20.6) 11 (26.8) 0.529
COPD, n (%) 4 (11.8) 6 (14.6) 0.716
Chronic renal disease, n (%) 8 (23.5) 11 (26.8) 0.744
Diabetes, n (%) 3 (8.8) 8 (19.5) 0.193
Immune suppression, n (%) 4 (11.8) 4 (9.8) 0.779
Nervous system disease, n (%) 5 (14.7) 5 (12.2) 0.698
Coronary heart disease, n (%) 11 (32.4) 14 (34.1) 0.870
No underlying disease 10 (29.4) 7 (17.1) 0.209
Death, n (%) 14 (41.2) 13 (31.7) 0.312
APACHE, Acute Physiology and Chronic Health Evaluation; COPD, chronic obstruc-
tive pulmonary disease.Materials and Methods
Patients
Patients for this study were selected from the respiratory care
unit and the surgical ICU at the PLA General Hospital in Beijing,
China, from January 2010 to March 2011. All of the
patients signed an informed consent form. Patients with sepsis
were divided into different groups based on either a clear or
highly suspected infection focus and at least 2 of the following
criteria: (1) body temperature either 438oC or o36oC; (2) heart
rate 490 beats/min; (3) either respiratory rate 420 times/min or
partial pressure of carbon dioxide in the arteries o32 mm Hg; or
(4) peripheral blood white blood cell count 412.0  109/L or
o4.0  109/L or immature neutrophils 410%.7 Severe sepsis was
associated with organ dysfunction, hypoperfusion, and hypoten-
sion. Patients with severe sepsis exhibited at least 1 of the
following: (1) hypoxemia (oxygenation index partial pressure of
oxygen in the arteries/fraction of inspired oxygen o300); (2) acute
renal injury as evidenced by either oliguria (urine output
o0.5 mL/kg/h for Z2 hours) or a serum creatinine increase of
40.5 mg/dL (44.2 mmol/L); (3) coagulation abnormalities, in
which activated partial thromboplastin time was 460 seconds,
international normalized ratio was 41.5 seconds, or platelet (PLT)
count was o100  109/L; (4) hyperbilirubinemia, in which total
bilirubin was either 44 mg/dL or 70 mmol/L; (5) metabolic
acidosis, in which either pH was o7.3 or lactic acid levels were
42 times higher than normal (lactic acidosis); and (6) infection-
associated hypotension, in which systolic blood pressure was
o80 mm Hg, mean arterial pressure (MAP) was o70 mm Hg, or
systolic blood pressure had a decrease of 440 mm Hg.8
The study exclusion criteria were the following: (1) o18 years
of age; (2) AIDS; (3) neutral neutropenia (polymorphonuclear
neutrophil count of o500 mL–1); (4) linezolid treatment course of
o7 days, and (5) use of chloramphenicol and thiamphenicol for
treatment.
Patient Groups and Treatments
All patients received either intravenous or oral linezolid for at
least 7 days for a gram-positive bacterial infection. We included
75 patients with sepsis in this study. One group received linezolid
only (linezolid treatment group [LTG]; n ¼ 41) and another group
received a combined treatment of linezolid and vitamin B6 as an
adjuvant therapy (combined treatment group [CTG]; n ¼ 34). We
further subdivided the LTG and the CTG into 2 subgroups: sepsis
and severe sepsis. For the CTG, there were 18 patients with sepsis
(CTG1) and 16 patients with severe sepsis (CTG2). For the LTG,
there were 26 patients with sepsis (LTG1) and 15 patients with
severe sepsis (LTG2).
For linezolid treatment, we used either linezolid intravenous
injections (300 mL [600 mg]/bag, lot number 09K20Z40; Frese-
nius Kabi Norge AS, Oslo, Norway) or linezolid tablets (600 mg/
tablet, batch number C100082; Pﬁzer Pharmaceuticals LLC, New
York, New York). The linezolid injection was 300 mL (600 mg)
administered intravenously, and the linezolid tablets were 600
mg, taken orally once every 12 hours. For the vitamin B6 adjuvant
treatment, we used an injection of amino acids (1 mL [50 mg]/support, production lot number approved by the state H12020522
products; Tianjin Jingyao Amino Acid Co, Ltd, Tianjin, China).
Vitamin B6 treatment was administered at 2 mL (50 mg) by
intravenous injection, to a total of 100 mg/d.6,9
Study Measurements
The study was approved by the local ethics committee. For
each patient, we recorded age, sex, days of drug compliance,
Acute Physiology and Chronic Health Evaluation (APACHE II)
scores, instances of a transfusion of blood products during
treatment, underlying diseases and mortality, and other general
information. We used routine clinical laboratory methods to
determine red blood cell (RBCs) counts, hemoglobin (Hb), hema-
tocrit (Hct), and PLT counts. These 4 indicators were determined
before medication administration (baseline, day 0) and on days 1,
3, 5, 7, 9, 11, 13, and 15 during the treatment course.
Statistical Methods
Data analysis was performed using SPSS (version 16.0 statis-
tical software; IBM, Armonk, New York). Results for continuous
variables are presented as means (SD) and were compared using
Student’s t-test. Results for categorical variables are given as the
number of cases (percentage) and compared using a w2 test. We
used repeated-measures ANOVA and independent sample
t-tests to compare the groups for differences at different
time points and by medication given before and during
treatment for laboratory test result changes in RBCs, Hb, Hct,
and PLT. A P value o0.05 was considered statistically signiﬁcant.Results
Patient Demographic Characteristics
Our CTG included 34 patients, and the LTG included 41
patients. As shown in Table I, patients in the CTG took their
medication for 15.9 (8.2) days, whereas those in the LTG took
their medication for 14.2 (6.2) days; these durations were not
signiﬁcantly different (P 4 0.05). There were also no signiﬁcant
differences between these groups in age, sex, APACHE II scores,
Figure 1. Trends in laboratory parameters with treatment time. (A) Red blood cell (RBC), (B) hemoglobin (Hb), (C) hematocrit (Hct), (D) platelet (PLT), (E) PLTs for septic
patients, and (F) PLTs for severe septic patients. nP o 0.05 compared with the linezolid treatment group before treatment. yP o 0.05 compared with the combined
treatment group before treatment. VB6, vitamin B6.
J. Deng et al. / Current Therapeutic Research 74 (2013) 26–3228the number of instances of a transfusion of blood products
during treatment, blood ﬁltration conditions, underlying disease
conditions, or mortality (P 4 0.05).
Trends in Hematology Results during the Treatment of Septic Patients
Red Blood Cell Counts
Figure 1A shows the trends in RBCs for septic patients in the LTG
and the CTG at different times during their treatments (Table II).
Compared with baseline (day 0) values, the RBC levels for septic
patients in the LTG showed a signiﬁcant reduction with time
starting on day 3. By comparison, patients in the CTG did not exhibitany obvious downward trend in RBCs over time, except for the ﬁrst
day of treatment, on which their RBC levels were slightly lower than
those before treatment (P o 0.05). Starting on day 9, the RBC results
of the CTG and the LTG were signiﬁcantly different (P o 0.05). This
illustrated that patients treated with linezolid alone had a more
signiﬁcant downward trend in RBC levels compared with patients
receiving linezolid treatment in combination with vitamin B6.Hemoglobin
Figure 1B shows that treatment with linezolid alone (LTG)
resulted in a signiﬁcant decrease in Hb levels over time compared
Table II
Repeated measures of the ANOVA results for red blood cell counts (RBCs), hemoglobin (Hb), hematocrit (Hct), and platelet counts (PLTs).
Time Points of
Observation, d RBCs
P
Hb
P
Hct
P
PLTs
P
PLTs in Nonsepsis Patients
P
PLTs in Severe Sepsis
Patients
PLTG CTG LTG CTG LTG CTG LTG CTG LTG CTG LTG CTG
0n 3.29
(0.71)
3.34
(0.59)
0.751 98.10
(19.31)
101.68
(17.77)
0.410 0.31
(0.06)
0.31
(0.06)
0.505 193.05
(102.88)
177.32
(131.27)
0.563 232.77
(98.60)
245.83
(142.67)
0.721 124.20
(69.80)
100.25
(53.58)
0.291
1st 3.18
(0.67)
3.18
(0.58)
0.995 97.05
(18.06)
97.41
(17.68)
0.930 0.30
(0.06)
0.30
(0.06)
0.831 183.78
(107.01)
155.82
(112.63)
0.470 222.92
(102.79)
225.00
(117.22)
0.951 113.60
(66.65)
96.81
(54.60)
0.448
3rd 3.16
(0.63)
3.18
(0.54)
0.841 96.39
(17.24)
98.35
(16.14)
0.620 0.30
(0.06)
0.30
(0.07)
0.356 174.17
(93.57)
164.21
(118.82)
0.686 214.19
(89.13)
225.44
(126.66)
0.728 104.80
(51.97)
95.31
(62.33)
0.650
5th 3.09
(0.69)
3.29
(0.50)
0.168 94.20
(17.61)
100.68
(17.76)
0.118 0.29
(0.06)
0.31
(0.05)
0.117 164.29
(90.65)
158.29
(115.26)
0.802 206.39
(81.96)
216.22
(116.00)
0.743 91.33
(49.90)
93.13
(73.63)
0.938
7th 3.10
(0.62)
3.27
(0.50)
0.163 94.12
(15.69)
101.35
(16.18)
0.054 0.29
(0.05)
0.31
(0.05)
0.130 161.76
(96.32)
161.53
(118.26)
0.993 207.12
(88.08)
218.39
(122.73)
0.724 83.13
(47.00)
97.56
(73.51)
0.523
9th 2.95
(0.58)
3.31
(0.56)
0.008 88.85
(15.58)
101.82
(16.82)
0.001 0.28
(0.05)
0.31
(0.06)
0.006 141.27
(88.63)
151.88
(108.61)
0.643 181.31
(83.16)
211.50
(109.14)
0.304 71.87
(44.24)
84.81
(58.21)
0.493
11th 2.88
(0.63)
3.26
(0.66)
0.015 87.00
(15.58)
99.24
(18.76)
0.004 0.27
(0.05)
0.30
(0.06)
0.004 126.68
(83.35)
145.85
(114.17)
0.406 163.65
(79.60)
209.33
(120.56)
0.137 62.80
(40.30)
74.44
(43.90)
0.449
13th 2.88
(0.63)
3.18
(0.65)
0.042 87.71
(16.48)
97.82
(20.47)
0.020 0.27
(0.05)
0.30
(0.06)
0.037 126.68
(88.60)
139.94
(112.03)
0.569 164.04
(87.95)
199.67
(120.90)
0.264 61.93
(39.10)
72.75
(44.16)
0.477
15th 2.86
(0.62)
3.15
(0.63)
0.050 87.76
(16.81)
96.74
(20.81)
0.042 0.27
(0.05)
0.29
(0.06)
0.046 125.00
(91.23)
135.15
(113.48)
0.669 163.27
(91.33)
193.61
(124.65)
0.356 58.67
(38.06)
69.38
(44.79)
0.480
P values represent the statistical differences between two groups at various time points of observation.
CTG, combined treatment group; LTG, linezolid treatment group.
n 0 indicates the initial day before treatment.
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J. Deng et al. / Current Therapeutic Research 74 (2013) 26–3230with the Hb levels before treatment (Table II). This slow decline
became apparent on day 5. For patients in the CTG, a reduction in
Hb levels was not obvious, except that the Hb levels on the ﬁrst
day of treatment compared with those before treatment were
lower (P ¼ 0.018). The Hb levels of the CTG and the LTG differed
signiﬁcantly from the ninth day onward, with lower Hb levels in
the LTG.
Hematocrit
The trends for the Hct are shown in Figure 1C (Table II).
Figure 1C shows that the Hct of the LTG appeared to decrease on
the ﬁfth day compared with patients in the CTG, and on the ninth
day, Hct was signiﬁcantly lower. However, in the CTG, a decline in
Hct was not obvious, with the exception that Hct on the ﬁrst day
of treatment was signiﬁcantly decreased compared with baseline
(day 0). With regard to the Hct, patients in the LTG had a
signiﬁcant downward trend compared with those in the CTG.
Platelet Counts
As shown in Figure 1D (Table II), septic patients in both the
LTG and CTG showed downward trends in their PLT counts during
treatment, although this time-dependent downward trend was
only statistically signiﬁcant in the LTG. However, there were no
signiﬁcant differences between these 2 groups at the different
observation times (P o 0.05).
Platelet Counts in Patients with Nonsevere Sepsis and Severe Sepsis
To further evaluate the declines in the PLT during treatment,
each patient group was further divided into subgroups of non-
severe sepsis and severe sepsis. The time-dependent trends for
nonsevere sepsis patients are shown in Figure 1E (Table II) and
for severe sepsis patients in Figure 1F (Table II). As shown in
Figure 1E for the 2 sepsis groups, there were no signiﬁcant
differences in the PLT count between these groups (P 4 0.05). In
the CTG, the PLT values did not statistically differ from baseline.
For patients with nonsevere sepsis in the LTG, during the course of
treatment, between 3 and 7 days, there was no signiﬁcant differ-
ence compared with samples taken before treatment. However,
starting on day 9, there was a signiﬁcant downward trend in the
PLT count.
As shown in Figure 1F for the 2 severe sepsis subgroups (LTG2
and CTG2), there were no statistically signiﬁcant differences
at any of the observation points. In the CTG, although
there appeared to be a downward trend in PLTs, this was
not statistically signiﬁcant. For severely septic patients in the
LTG, statistically signiﬁcant differences from baseline were
observed from the ﬁfth day onward during the course of treat-
ment. It should be noted that, overall, the PLT values were lower
for severely septic patients (Figure 1F) compared with patients
with nonsevere sepsis (Figure 1E) regardless of the treatment
regimen.Discussion
Sepsis is a condition caused by systemic inﬂammation and is
1 of the leading causes of death in the ICU. Although in-depth
studies have been conducted on both the pathogenic mechanisms
of sepsis and its pathophysiology in recent years and more
treatments have been discovered, the high morbidity and mor-
tality associated with infection remain difﬁcult to counteract.10 In
an epidemiological survey of surgical ICUs in 10 teaching hospi-
tals located in 6 Chinese provinces, 53.8% of patients were treated
for gram-positive infections, 45.9% of patients were treated for
gram-negative bacterial infections, and 22% of patients weretreated for invasive fungal infections.11 Gram-positive strains
were the major pathogenic strains associated with sepsis.
Linezolid was the ﬁrst oxazolidinone antibiotic to be approved
for treating gram-positive bacterial infections.3 It not only exhi-
bits excellent therapeutic effects against multiple resistant gram-
positive bacteria such as vancomycin-resistant Enterococcus fae-
calis, MRSA, and multidrug-resistant strains,12 but it also has
antibacterial activities against anaerobic bacteria and atypical
mycobacteria.13,14 However, as the use of linezolid has become
more widespread in clinical practice, several adverse outcomes
have been observed in patients who received long-term linezolid
treatments.
After using the drug for 42 weeks, adverse outcomes primarily
affecting the hematopoietic system were reported, including
anemia and thrombocytopenia.4 In a study of disseminated
mycobacterial infections in which patients received both linezolid
and vitamin B6, Spellberg et al5 observed that vitamin B6
might reduce or even prevent linezolid-related thrombo-
cytopenia. Subsequently, in a retrospective study of 24 patients
with bone marrow infections who received both linezolid and
vitamin B6, the opposite conclusion was found, in that adjuvant
treatment with vitamin B6 for sepsis in combination with
linezolid did not reduce linezolid-related hematologic
adverse outcomes.9 In a study by Youssef et al,15 who used
linezolid and vitamin B6 as an adjuvant therapy for 31 cancer
patients complicated by infections, vitamin B6 reduced secondary
anemia, but it did not prevent the reduction in PLT and leukocyte
counts.
Our retrospective clinical study found that patients who
were treated for sepsis with linezolid had reductions in RBC
counts, Hb, Hct, and PLT counts. On the ﬁrst day of observation for
the linezolid and vitamin B6 treatment group, the RBC, Hb, and
Hct levels were signiﬁcantly lower than baseline, but throughout
the remainder of the treatment course used in this study the
downward trend observed just after treatment began did not
signiﬁcantly change. Septic patients who received vitamin B6
combined with linezolid also showed similar effects for PLT
counts, although the downward trend in PLTs was only statisti-
cally signiﬁcant after the ﬁrst 13 days of treatment. Thus, it could
be inferred that vitamin B6 used in adjuvant therapy could
prevent linezolid-related reductions in blood cells to some extent,
and although it was highly effective for red cells, its effects on
thrombocytopenia might not be as obvious.
Hb is comprised of heme and globin, and vitamin B6 is
essential for hemoglobin synthesis. It participates in the synth-
esis of a heme precursor, -d-amino-g-keto acid, and is a
d-amino-g-keto acid synthesis enzyme cofactor.16 Sideroblastic
anemia is deﬁned as a vitamin B6 genetic factor heme synthesis
pathway disorder. This Hb gene mutation may occur in cell
anemia, small cell anemia, and megaloblastic anemia; thus,
vitamin B6 treatment is useful for such patients.17 Additionally,
linezolid inhibits mitochondrial protein synthesis and blocks
mitochondrial respiration, which may cause sideroblastic ane-
mia, because RBCs produce an important factor to counteract
this effect.18
In our CTG, the RBCs, Hb, and Hct were only signiﬁcantly lower
on the ﬁrst day after starting treatment. Concurrently, the LTG
exhibited signiﬁcant reductions in the RBC counts over time,
indicating that linezolid might cause a temporary RBC gene
mutation and temporarily inhibit mitochondrial respiration,
which would result in this type of anemia in these patients.
Vitamin B6 could promote the synthesis of hemoglobin, which
could restore the RBCs in the later periods of treatment and
maintain the levels observed before treatment. It could be
inferred that linezolids might play a critical role by affecting RBCs
and reducing the RBC pigment metabolic pathway.
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bocytopenia might be immune-mediated,19 which was similar to
the mechanism associated with quinine and/or quinidine-like
immune-mediated thrombocytopenia. This immune-related
thrombocytopenia is due to either a drug or its metabolites
binding to either the PLT membrane glycoprotein 1b/IX or
glycoprotein IIb/IIIa, which produces an immunogenic compound
of immunoglobulin-G and a Fab fragment. Immunoglobulin-G
and an Fc fragment can combine with macrophages and be
cleared by the reticuloendothelial system, resulting in thrombo-
cytopenia.20,21
In this study, patients treated with both linezolid and vitamin
B6 did show changes in PLTs during the ﬁrst 9 days of medication
use, but these changes in PLTs were not statistically signiﬁcant
until 13 days after initiation of treatment compared with the
samples taken before treatment began. In the sepsis subgroups
CTG1 and LTG1, there was a downward trend despite the fact that
the CTG and 2 patients in the LTG did not show signiﬁcant
differences at each observation point. In particular, the decline
observed in the CTG was obviously slower. In the severe sepsis
subgroups CTG2 and LTG2, the downward trend in the group
treated with linezolid alone was clearly more evident, although
the PLT counts were not signiﬁcantly different at each observation
point. We speculated that vitamin B6 given to septic patients with
linezolid-related thrombocytopenia might slow the loss of PLTs,
but this was not conclusive.
It was reported that linezolid blood levels might affect
hematopoietic function and that clearance of linezolid was closely
related to Hb levels.22 We speculated that this latter mechanism
involved alterations in PLT dynamics by vitamin B6. This might
due to the maintenance of Hb levels, which could increase the
clearance of linezolid and reduce its accumulation in the body,
thus reducing the chance of immune complex formation when
linezolid binds to either the membrane glycoprotein 1b/IX or
glycoprotein IIb/IIIa. Thus, there would not be a signiﬁcant
reduction in PLT counts. However, with an extended treatment
time, there was a clear reduction in the PLT count, which
suggested that there was no signiﬁcant effect on the ability of
vitamin B6 to reduce PLT counts.
This retrospective study had some limitations. First, this was
a single-center retrospective study; thus, the experimental
controls were not ideal. Second, because the overall sample size
was small, the power of the statistical tests might have been
reduced, so the probability of signiﬁcant reductions might have
been low. Third, the patients only received medication for
approximately 14 days, which might have caused some limita-
tions with regard to medication use duration. Finally, this study
used both oral and intravenous administration; the route of
administration for different drugs could affect the occurrence of
adverse reactions because these depend on bioavailability and
pharmacokinetic parameters.23 We could speculate that the
bioavailability and pharmacokinetic parameters of intravenously
infused linezolid might be different from those of orally admi-
nistered linezolid. In this retrospective study, we did not distin-
guish between intravenous and oral administration. Thus, we
could not rule out that a different route of linezolid administra-
tion might reduce the observed effects on the measured blood
cell parameters.
In summary, patients who received linezolid for extended
periods could develop linezolid-related cytopenias. Thus, before
and during treatment, we should closely monitor changes in
hematologic parameters. Care should be taken during sympto-
matic treatment to stop administration of the medicine when
reductions in blood cell counts are noted. In this preliminary
retrospective study, we found that administering linezolid, along
with adjuvant treatment with vitamin B6, to patients with sepsiseither prevented or delayed the reductions in the RBC counts to a
certain extent, whereas no improvement was observed in the
development of thrombocytopenia. Vitamin B6 is a low-cost
supplement with few side effects. Thus, its use in conjunction
with linezolid could be regarded as an effective method to reduce
blood cell counts. These observations will require either addi-
tional studies with larger sample sizes or a prospective study to
conﬁrm the effects noted here. Furthermore, studies must also be
conducted regarding the mechanisms involved with vitamin B6 to
prevent and treat linezolid-related pancytopenia.Acknowledgments
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